Martinelli Nicola, Micaglio Roberta, Consoli Letizia, Guarini Patrizia, Grison Elisa, Pizzolo Francesca, Friso Simonetta, Trabetti Elisabetta, Pignatti Pier Franco, Corrocher Roberto, Olivieri Oliviero, Girelli Domenico
Department of Medicine, University of Verona, Policlinico G.B. Rossi, Italy.
Exp Diabetes Res. 2012;2012:231502. doi: 10.1155/2012/231502. Epub 2011 Sep 22.
Low concentrations of plasma high-density lipoprotein (HDLs) are characteristic in metabolic syndrome (MS). The antioxidant ability of HDLs is, at least in part, attributable to pleiotropic serum paraoxonase (PON1). Different PON1 activities have been assessed in 293 subjects with (n = 88) or without MS (n = 205) and with (n = 195) or without (n = 98) angiographically proven coronary artery disease (CAD). MS subjects had low PON1 activities, with a progressively decreasing trend by increasing the number of MS abnormalities. The activity versus 7-O-diethyl phosphoryl,3-cyano,4-methyl,7-hydroxycoumarin (DEPCyMC), which is considered a surrogate marker of PON1 concentration, showed the most significant association with MS, independently of both HDL and apolipoprotein A-I levels. Subjects with MS and low DEPCyMCase activity had the highest CAD risk (OR 4.34 with 95% CI 1.44-13.10), while no significant increase of risk was found among those with MS but high DEPCyMCase activity (OR 1.45 with 95% CI 0.47-4.46). Our results suggest that low PON1 concentrations are typical in MS and may modulate the MS-related risk of CAD.
血浆高密度脂蛋白（HDL）浓度低是代谢综合征（MS）的特征。HDL的抗氧化能力至少部分归因于多效性血清对氧磷酶（PON1）。对293名有（n = 88）或无MS（n = 205）以及有（n = 195）或无（n = 98）血管造影证实的冠状动脉疾病（CAD）的受试者评估了不同的PON1活性。MS受试者的PON1活性较低，随着MS异常数量的增加呈逐渐下降趋势。与7-O-二乙基磷酰基、3-氰基、4-甲基、7-羟基香豆素（DEPCyMC）的活性，DEPCyMC被认为是PON1浓度的替代标志物，显示出与MS最显著的关联，独立于HDL和载脂蛋白A-I水平。MS且DEPCyMCase活性低的受试者CAD风险最高（OR 4.34，95%CI 1.44 - 13.10），而MS但DEPCyMCase活性高的受试者中未发现风险显著增加（OR 1.45，95%CI 0.47 - 4.46）。我们的结果表明，低PON1浓度是MS的典型特征，可能调节与MS相关的CAD风险。
